The dossier submitted by Australia-based medical cannabis and hemp company, Bod, has been validated to progress to receive a registration for the company’s exclusive CBD extract as a novel food.
The approval, which is expected in the coming months, will allow Bod to continue distributing product ranges in the UK.
If registered, it will provide Bod with the opportunity to pursue additional partnerships to introduce new products across a range of verticals.
Bod CEO, Jo Patterson, said: “The ownership of a Novel Food Registration adds significant value to the exclusive extract Bod uses across our products in the consumer healthcare market. This step is the result of a significant amount of work over the last 12 months. It is great to have achieved this milestone and we are keen to explore the opportunities it will bring.
Read more: FSA permitted CBD products list to be published imminently
“While there are a wide range of CBD products available in the UK, the recent regulatory changes are anticipated to lead to a consolidation in the sector, as those products without a valid registration will need to cease to sell. The company has been exploring product range expansion options for some time and multiple verticals have been earmarked for growth.
“We look forward to updating shareholder as approvals are granted and other developments materialise.”
The company undertook significant background work to support the application, including toxicology studies and stability testing – the data of which will support an additional Novel Food registration for European Union (EFSA) in coming months Sydney, Australia. The company has stated that European novel foods registration is expected to unlock several additional opportunities, allowing Bod to broaden its global footprint.
Read more: British Cannabis celebrate products receiving confirmation from FSA
Bod has an already established footprint in the UK and currently distributes both medicinal cannabis and CBD wellness products in the region – selling 15 CBD wellness products through its global partner, Health & Happiness Group Limited under brands CBII and Swisse.
The company recently announced the launch of a UK-based trial in association with the country’s independent scientific body on drugs, Drug Science, to explore the potential of medical cannabis as a treatment for long covid, and its medical cannabis product – MediCabilis – is available through the special access market through a prescription.
Initiatives have begun to begin the trial, which is recruiting up to 30 participants over the age of 18 suffering from long covid. Patients taking part in the trial will be administered MediCabilis every day for six months, and will undertake monthly and daily assessment of symptoms such as breathlessness, fatigue, cognition and pain via a smartphone app.
[activecampaign form=31]
